[Vision for patients with macular degeneration].
Paukstadt
Waldtraud
W
D020533:Angiogenesis Inhibitors / Q000191:economics / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002017:Budgets; D003363:Cost Control; D017277:Drug Approval; D016527:Drug Costs; D005858:Germany; D006801:Humans; D007262:Infusions, Intravenous; D008268:Macular Degeneration / Q000175:diagnosis / Q000188:drug therapy* / Q000191:economics; D009313:National Health Programs / Q000191:economics
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab